Results 161 to 170 of about 58,391 (264)

Rapid Discovery of CD38 Inhibitor via DNA-Encoded Natural Product Library Screening. [PDF]

Molecules
Shi X, Liang Z, Meng W, Yang G, Yan L.
europepmc   +1 more source

Passenger variants as pan‐clonal markers of pediatric AML: Implications for molecular MRD

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract A streamlined, sensitive, and universal molecular method for MRD detection in pediatric AML remains an unmet clinical need. Here, we propose a novel approach based on tracking somatic non‐coding passenger variants. Using whole‐genome sequencing (WGS) of diagnostic bone marrow DNA, we identify patient‐specific somatic passenger variants, which ...
Ruth Shiloh, Dana Dayan, Ifat Geron, Maor Cohen, Tamar Feuerstein, Jorge Cano‐Nistal, Nurit Gal‐Mark, Shlomit Barzilai‐Birenboim, Dafna Gaash, Michal Hameiri‐Grossman, Avraham Kahan, Jamal Mahajna, Nino Oniashvili, Hava Rosenfeld, Dan Scharf, Keren Shichrur, Elena Shinderman‐Maman, Sarah Elitzur, Yehudit Birger, Shai Izraeli, Yosef E. Maruvka   +20 more
wiley   +1 more source

Validation of the new IMS/IMWG consensus genomic staging (CGS) of high‐risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract Due to its high clinical and biological complexity, multiple myeloma (MM) is a malignancy of heterogeneous prognoses and outcomes. The International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) formulated a consensus genomic staging (CGS) of high‐risk MM (HRMM), aiming to refine and homogenize the classification of high ...
Efstathios Kastritis, Charalampos Filippatos, Maria Gavriatopoulou, Foteini Theodorakakou, Eirini Solia, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis‐Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Aikaterini Vlachou, Despina Fotiou, Konstantinos Giannakas, Erasmia Boutakoglou, Stavroula Giannouli, Panagiotis Tsirigotis, Asimina Papanikolaou, Evangelos Terpos, Meletios A. Dimopoulos   +20 more
wiley   +1 more source

Enhanced Human Antigen-Specific B Cell Responses Using In Vitro 3D Tonsil Cultures Containing Stromal Cells. [PDF]

Adv Healthc Mater
Braham MVJ, de Gast M, Babii L, Kruijer S, Bestebroer TM, Richard M, Claireaux M, van Ham SM, de Wit J, van Els CACM, Ten Brinke A, van Gils MJ.   +11 more
europepmc   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

NAD⁺‒circadian rhythm coupling in dementia. [PDF]

Alzheimers Dement
Zhang SQ, Lee J, Pan JP, Enger R, Hrubos-Strøm H, Musiek ES, Fang EF, Le W.   +7 more
europepmc   +1 more source

Rituximab Binding Endows CD20+ Extracellular Vesicles With NK Cell‐Activating Properties in B Cell Lymphoma

Journal of Extracellular Vesicles, Volume 15, Issue 8, August 2026.
B cell lymphoma‐derived EVs are intrinsically neutral or suppressive with respect to NK cell activity (panel 1). In the context of rituximab treatment, NK cytotoxicity is enhanced by antibody‐dependent cell‐mediated cytotoxicity (panel 2). Herein we show that, in addition, rituximab recognition of EV‐associated CD20 generates immune complexes that ...
Adrián V. Otero, Paula Soledad Pérez, Belen Gaete‐Ramírez, Gregorio Cordini, Matías Norte, Enriqueta Martínez, Nicolás Marsol, Cecilia Malusardi, Sofía Rivarola, Ana Cantillo, María Luz Leicaj, Constanza Russo, Juan Quarroz Braghini, Federico Penas, Glenda Ernst, Cecilia Cabral, Silvina Palmer, Manuel Varas‐Godoy, Lourdes Arruvito, Matías Ostrowski   +19 more
wiley   +1 more source

A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia. [PDF]

Blood Cancer J
Parrondo RD, Ailawadhi S, Knopf BR, Zimmerman A, Kasik CJ, Chapin D, Heslop K, Roy V, Paulus A, Chanan-Khan AA.   +9 more
europepmc   +1 more source

Mitigating Teclistamab Toxicity: Prophylactic Tocilizumab and Timing of Immunoglobulin Replacement Therapy in a Nationwide Cohort

American Journal of Hematology, Volume 101, Issue 8, Page 2081-2085, August 2026.
Astrid Hundebøll Torpe, Jonathan Thorsen, Gustav Mathiasen, Katrine Fladeland Iversen, Sarah Farmer, Thomas Lund, Charlotte Toftmann Hansen, Lene Kongsgaard Nielsen, Nicolai Grønne Dahlager Jørgensen, Maja Ølholm Vase, Elena Manuela Teodorescu, Morten Salomo, Christina Wennerström, Tobias S. Slørdahl, Agoston Gyula Szabo   +14 more
wiley   +1 more source

Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2‐Year Follow‐Up From MajesTEC‐1 China Cohort

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction With an additional year of follow‐up compared with the previous report, this study presents the 27.2‐month efficacy and safety outcomes of the MajesTEC‐1 China cohort. Methods A total of 26 participants with triple‑class exposed relapsed/refractory multiple myeloma (TCE‐RRMM) received subcutaneous teclistamab 1.5 mg/kg weekly ...
Zhen Cai, Zhongjun Xia, Aili He, Yujun Dong, Yafei Wang, Aijun Liao, Yang Song, Hongye Chen, Athena Zuppa, Katherine Chastain, Latisha Watkins, Xinchao Luo, Lin Huang, Hongmei Xu, Longen Zhou, Wannan Chen, Angeline Zhu, Xiaohong Wang, Weijun Fu, Ting Niu, Juan Du   +20 more
wiley   +1 more source